Praluzatamab ravtansine

Synonyms: CX-2009

Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.

Praluzatamab ravtansine

CAS No. 2145115-85-9

Purity & Quality Control

Choose Selective CD markers Inhibitors

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 5
AB680 0
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53
LY-3475070
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.

Product Details

CAS No. 2145115-85-9
ADC antiody Praluzatamab
ADC cytotoxin DM4
Formulation 1xPBS
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Praluzatamab ravtansine | Praluzatamab ravtansine supplier | purchase Praluzatamab ravtansine | Praluzatamab ravtansine cost | Praluzatamab ravtansine manufacturer | order Praluzatamab ravtansine | Praluzatamab ravtansine distributor